Molecular Oncology Almanac
  • API
  • Approvals
  • Organizations
  • About
  • Contact

Pertuzumab/Trastuzumab (Phesgo) and Weekly PACLitaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Pertuzumab/Trastuzumab (Phesgo) and Weekly PACLitaxel Therapy - 21 day cycle, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/797-pertuzumab-trastuzumab-phesgo-and-weekly-paclitaxel-therapy-21-day-cycle.pdf

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
Pertuzumab/trastuzumab (Phesgo) is indicated in combination with PACLitaxel in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease where patients are intolerant of, have had significant toxicity to or are deemed clinically unsuitable for DOCEtaxel 1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Paclitaxel, Pertuzumab, Trastuzumab

Please review our privacy policy and terms before use.
API | Bluesky | Contact | GitHub

  • Dana-Farber logo
  • University of Limerick Digital Health Center logo
  • eHealthHub logo